We often get asked what the commercial opportunity for Pixuvri is in the EU. So to assess the market size in addition to our own internal forecast, we engaged Kantar research, who conducted what they call in-market research in the EU among 251 lymphoma specialists in the 5 major market countries, capturing data on their current treatment practices for patients who are third or fourth line who have aggressive B-cell non-Hodgkin's lymphoma, and how those practices would potentially change with the introduction of Pixuvri.
Now it's important to keep in mind, our labeled indication is in the third and fourth line B-cell aggressive NHL. And in that subset of 112 patients, the CR/CRu rate was 28% for Pixuvri versus 4% for comparator, and overall response rate was 48% for Pixuvri compared to 12% for comparative single therapy. And at 2 years of follow up, there was a 50% reduction in the risk of death or relapse, the so-called progression-free survival, with the median overall survival for Pixuvri on being 13.9 months versus 7.8 months for the comparative active chemotherapeutic agent.
So these are the data that we'll focus on with the help and payers -- health authorities and payers when considering the value proposition for Pixuvri in this patient population. And based on Kantar's research, their analyses, including their discounts, we're encouraged by the projected market opportunity for Pixuvri in the EU given the percentage of physicians who noted that they would integrate Pixuvri into their current treatment practices for patients with relapsed aggressive B-cell non-Hodgkin's lymphoma. And we look forward to updating you as we initiate market introduction and begin to get an indication of product demand.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts